Sign Up to like & get
recommendations!
0
Published in 2018 at "Schizophrenia Research"
DOI: 10.1016/j.schres.2018.06.064
Abstract: Eye movement abnormalities have been reported in schizophrenia; however, their influences on everyday life remain unknown. From data on 69 subjects with schizophrenia and 246 healthy subjects, we found positive correlations between eye movement measures…
read more here.
Keywords:
abnormalities eye;
eye movement;
subjects schizophrenia;
work hours ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Translational Psychiatry"
DOI: 10.1038/s41398-018-0353-x
Abstract: Subjects with schizophrenia have high risks of metabolic abnormalities and bioenergetic dysfunction. Acyl-carnitines involved in bioenergetic pathways provide potential biomarker targets for identifying early changes and onset characteristics in subjects with schizophrenia. We measured 29…
read more here.
Keywords:
acyl carnitines;
subjects schizophrenia;
pre post;
post treatment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Translational Psychiatry"
DOI: 10.1038/s41398-021-01430-7
Abstract: The status of serotonin 5HT 2A receptors (5HT 2A Rs) in schizophrenia has been controversial. In vivo positron emission tomography neuroimaging and in vitro post-mortem binding studies have reported conflicting results about 5HT 2A R…
read more here.
Keywords:
inverse agonist;
pharmacological profile;
subjects schizophrenia;
density ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Clinical and translational science"
DOI: 10.1111/cts.13512
Abstract: This study (NCT04369391) evaluated the effects of ulotaront (SEP-363856), a novel trace amine-associated receptor 1 (TAAR1) agonist in development for schizophrenia, on electrocardiogram parameters. Study design was a randomized, single-dose, 3-period crossover (ulotaront 150 mg,…
read more here.
Keywords:
single dose;
crossover;
effects ulotaront;
subjects schizophrenia ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Psychopharmacology"
DOI: 10.1177/0269881119857205
Abstract: Background: The endocannabinoid system – comprising cannabinoid receptors, endocannabinoid ligands and their synthesis and inactivation enzymes – has been widely implicated in the pathophysiology of schizophrenia. However, little is known regarding the status of the…
read more here.
Keywords:
endocannabinoid system;
subjects schizophrenia;
system;
prefrontal cortex ... See more keywords